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A disk potentiation method using carbapenems as substrates and 3-aminophenyl boronic acid as an
inhibitor was evaluated for the detection of Klebsiella pneumoniae carbapenemase (KPC)-type -lactama-
ses. When combined with nonsusceptibility to ertapenem, the method was easy to perform and reliably
differentiated isolates producing KPC-type -lactamases from those producing other types of -
lactamases.
Since the initial report in 2001 (24), carbapenem resis-
tance mediated by the production of Klebsiella pneumoniae
carbapenemase (KPC)-type -lactamases is increasingly
identified in the United States and more recently worldwide
(3, 22). Initially confined mostly to K. pneumoniae, these
enzymes are now reported in various species of Enterobac-
teriaceae as well as Pseudomonas aeruginosa (7, 16, 21).
Clinically, infections due to KPC-producing strains of En-
terobacter spp. have been associated with increased mortality
in affected patients (14). From the infection control stand-
point, KPC-producing K. pneumoniae and Escherichia coli
have caused outbreaks in acute-care hospitals and long-
term-care facilities, respectively (4, 19, 22). However, labo-
ratory detection of these organisms is difficult (5, 20). Sev-
eral methods have been developed specifically for the
detection of KPC-producing Enterobacteriaceae. A method
that utilizes nonsusceptibility to ertapenem for screening
followed by confirmation using the modified Hodge test has
been proposed (1). In the modified Hodge test, a carbap-
enem disk is placed on a Mueller-Hinton agar plate inocu-
lated with E. coli ATCC 25922. The test strain is then
streaked radially from the edge of the disk to the periphery
of the plate. After an overnight incubation, the presence of
a distorted inhibition zone indicates the carbapenem-hydro-
lyzing activity of the test strain. This method is relatively
easy to perform and feasible in clinical laboratories but
requires some experience in interpreting the results. A
method measuring the hydrolysis of carbapenems by cell
extracts has been reported as well, though this method is
technically demanding and requires specialized laboratory
equipment (15).
Boronic acid compounds are known to be excellent inhib-
itors of class C -lactamases (2, 13). One such compound,
3-aminophenyl boronic acid (APB), has recently been used
successfully in detecting the production of plasmid-medi-
ated class C -lactamases in Enterobacteriaceae (6, 10, 12,
23). We have subsequently undertaken a study investigating
the effects of APB on zone diameters of carbapenem-con-
taining disks in a set of isolates producing KPC-type -lac-
tamases as well as other non-KPC broad-spectrum -lacta-
mases.
A total of 23 epidemiologically unrelated K. pneumoniae
and E. coli clinical isolates (10 producing KPC-type -lac-
tamase, 3 ertapenem-resistant isolates without KPC-type
-lactamase, 5 producing extended-spectrum -lactamase
[ESBLs], and 5 producing plasmid-mediated class C -lac-
tamase) were included in the study. Specifically, the KPC-
producing isolates originated from five hospitals in three
states. We also included E. coli DH10B strains carrying
recombinant plasmids that bear the genes for the metallo-
-lactamases (MBLs) IMP-1 and VIM-2. The -lactamase
types were determined by PCR analysis and nucleotide se-
quencing as appropriate. For the detection and sequencing
of the KPC gene, primers KPC-1-F (5-GGC TTG CCG
CTC GGT GAT ATT-3) and KPC-1-R (5-TAT CTG TGA
GGG CGA AGG TTA-3) were used at an annealing tem-
perature of 62°C. ESBL genes and plasmid-mediated class C
-lactamase genes were amplified as described previously
(11, 18). The isolates were suspended in and diluted with
normal saline to 108 CFU/ml by comparison with a McFar-
land 0.5 turbidity standard and spread on a Mueller-Hinton
agar plate (BD Microbiology Systems, Sparks, MD) as rec-
ommended by the Clinical and Laboratory Standards Insti-
tute (CLSI) (8). The following disks (BD Microbiology Sys-
tems) were tested: ertapenem (10 g), ertapenem (10 g)
with APB (300 g), imipenem (10 g), imipenem (10 g)
with APB (300 g), meropenem (10 g), meropenem (10
g) with APB (300 g), ceftazidime (30 g), and ceftazi-
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dime (30 g) with APB (300 g). APB (3-aminophenyl
boronic acid hydrochloride; Sigma-Aldrich, St. Louis, MO)
was dissolved in water at 50 mg/ml, and 6 l was applied per
disk. The amount of APB to be applied to the disks was
determined based on the following observation: when the
inhibitory effects of APB on representative KPC-positive
and -negative isolates were examined at 100, 200, 300, 450,
and 600 g per disk, 300 g was found to provide optimal
sensitivity and specificity in detecting the presence of KPC-
type -lactamase when combined with ertapenem or mero-
penem, and a cutoff of a 5-mm difference in zone diameter
was used. The zone diameters were read by at least two
microbiologists. The modified Hodge test was performed to
confirm the production of carbapenem-hydrolyzing -lacta-
mase as described previously (1).
The results are summarized in Table 1. The modified Hodge
test was positive for all 10 KPC-producing clinical isolates and
2 MBL-producing laboratory strains, confirming the presence
of significant carbapenem-hydrolyzing activity. None of the
other isolates had positive results with the modified Hodge
test. All 10 KPC-producing isolates were resistant to ertap-
enem, intermediate or resistant to meropenem, and variably
resistant to imipenem. Ertapenem and meropenem were both
sensitive substrates for potentiation by APB. When APB was
added to ertapenem or meropenem disks, an increase in zone
diameter of 5 mm was observed for all KPC-producing iso-
lates (Table 1; Fig. 1). Potentiation of 5 mm was observed in
6 of the 10 isolates for imipenem. On the other hand, none of
the three ertapenem-resistant isolates without KPC-type -lac-
tamase or the two MBL-producing strains produced a 5-mm
increase in zone diameter with any of the carbapenems when
combined with APB. Of note, all five isolates producing plas-
mid-mediated class C -lactamase gave a5-mm increase with
ertapenem when combined with APB but not with imipenem
or meropenem. However, they were all susceptible to ertap-
enem and were thus unlikely to be screened for the presence of
KPC-type -lactamase.
The mechanism for inhibition of KPC-type -lactamase by
APB is not known. A recent report from Argentina described
the inhibition of the carbapenem-hydrolyzing activity of crude
extracts from KPC-producing K. pneumoniae by APB (17). The
authors cautioned that synergism between APB and KPC
could lead to a false assumption of class C -lactamase pro-
duction. However, our results suggest that APB may have a
role in the phenotypic confirmation of KPC production. Non-
susceptibility to ertapenem has been reported to be an excel-
lent indicator of the presence of KPC-type -lactamase with
sensitivity exceeding 90% (1). Therefore, a two-tiered detec-
tion method, i.e., screening for ertapenem nonsusceptibility
followed by confirmation with a disk potentiation test between
ertapenem or meropenem and APB, appears to be a viable
approach in identifying KPC-producing K. pneumoniae and E.
coli. Our study is limited by the relatively small number of
isolates assessed, especially ertapenem-resistant isolates with-
out KPC-type -lactamase. However, if replicated on large,
diverse samples of KPC producers and nonproducers, this
method holds promise for the busy clinical microbiology lab-
oratory since the algorithm is analogous to the ESBL detection
method using disk diffusion as defined by the CLSI (9), thus
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making it easy for the laboratory staff to incorporate it into
daily practice.
Y.D. was supported by NIH training grant T32AI007333. D.L.P. is
supported in part by NIH research grant R01AI070896.
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